SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 14, 2002; DOI 10.1182/blood-2002-02-0651. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-02-0651v1 100/3/774    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Milledge, J. Articles by Christodoulou, J. Search for Related Content PubMed PubMed Citation Articles by Milledge, J. Articles by Christodoulou, J. Related Collections Transplantation Clinical Trials and Observations Related Letters in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2002, Vol. 100, No. 3, pp. 774-777 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Allogeneic bone marrow transplantation: cure for familial Mediterranean fever John Milledge, Peter J. Shaw, Albert Mansour, Sarah Williamson, Bruce Bennetts, Tony Roscioli, Julie Curtin, and John Christodoulou From the Oncology Department, Department of Paediatrics, Western Sydney Genetics Program, Department of Haematology, Royal Alexandra Hospital for Children, Sydney, Australia; and Department of Paediatrics and Child Health, University of Sydney, Sydney, Australia. We describe data on a 7-year-old girl with congenital dyserythropoietic anemia (CDA), who also had familial Mediterranean fever (FMF). Repeated transfusions required since the age of 6 months to treat her CDA led to iron overload and a persistently high ferritin level. Her relapsing FMF made effective iron chelation therapy very difficult. Consequently, at the age of 4 years, she underwent allogeneic, sibling bone marrow transplantation (BMT). During conditioning for her BMT, symptoms of FMF, including splenomegaly, arthritis, and recurrent abdominal pain, began to resolve and she was gradually weaned off colchicine. Now, 2 years after the transplantation, she remains free from FMF symptomatology and is off all immunosuppressants. This case demonstrates that symptoms of FMF can be alleviated by the therapy used during allogeneic BMT. In this patient it is likely that the missing factor in FMF is now being provided by granulocytes derived from the stem cells within transplanted bone marrow. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letters in Blood Online: Should patients with FMF undergo BMT? Isabelle Touitou, Peter J. Shaw, John Christodoulou, and Albert Mansour Blood 2003 101: 1205. [Full Text] [PDF] Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever Isabelle Touitou, Eldad Ben-Chetrit, Ruth Gershoni-Baruch, Gilles Grateau, Daniel L. Kastner, Isabelle Kone-Paut, Avi Livneh, Raffaele Manna, Issam Mansour, Huri Ozdogan, Seza Ozen, Tamara Sarkisian, Mehmet Tunca, and Fatos Yalcinkaya Blood 2003 102: 409. [Full Text] [PDF] This article has been cited by other articles: I. Touitou, E. Ben-Chetrit, R. Gershoni-Baruch, G. Grateau, D. L. Kastner, I. Kone-Paut, A. Livneh, R. Manna, I. Mansour, H. Ozdogan, et al. Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever Blood, July 1, 2003; 102(1): 409 - 409. [Full Text] [PDF] I. Touitou, P. J. Shaw, J. Christodoulou, and A. Mansour Should patients with FMF undergo BMT? Blood, February 1, 2003; 101(3): 1205 - 1205. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020